Q-omics provides the consensus-scored CC2D1A profile across patient tissues and cancer cell-line models. CC2D1A expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CC2D1A is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, CC2D1A RNA expression shows 18,999 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRP, and ACC as cancer lineages where CC2D1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CC2D1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CC2D1A survival associations across molecular data types. CC2D1A RNA expression shows survival associations in the most cancer types (30), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CC2D1A RNA expression–survival associations across cancer types. High CC2D1A expression shows unfavorable associations in KICH, LGG, ACC and LAML, but favorable associations in HNSC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CC2D1A RNA expression.
This table summarizes CC2D1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CC2D1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CC2D1A shows higher tumor expression in KIRP, LIHC, HNSC, STAD, LUSC and UCEC. The KIRP box plot shows higher CC2D1A RNA expression in tumor versus normal tissue (log2 FC = +0.613, t-test p < 0.001).
This table shows molecular features associated with CC2D1A in patient tissues and cancer cell lines. In patient samples, CC2D1A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CC2D1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
